Respiratory viruses and severe lower respiratory tract complications in hospitalized patients

被引:73
作者
Garbino, J
Gerbase, MW
Wunderli, W
Kolarova, L
Nicod, LP
Rochat, T
Kaiser, L
机构
[1] Univ Hosp Geneva, Cent Lab Virol, Div Infect Dis, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Div Pulm Med, CH-1211 Geneva 14, Switzerland
关键词
adenovirus; BAL; immunocompromised host; influenza; parainfluenza virus; respiratory syncytial virus; rhinovirus; viral infection;
D O I
10.1378/chest.125.3.1033
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Acute respiratory viral infections are generally self-limited in healthy subjects but can lead to severe complications in immunocompromised hosts. We report the clinical impact of acute lower respiratory tract viral infections in hospitalized patients. Materials and methods: Of 1,001 fiberoptic bronchoscopies performed during a period of 5 years, 33 BAL samples were positive for respiratory viruses by cell culture. The main diagnosis, length of hospitalization, response to initial treatment, and the mortality rate at 30 days were analyzed. Spirometry performed before and after infection was compared in lung transplant recipients. Results: The following respiratory viruses were identified in 33 cases: influenza A or B (n = 13), parainfluenza virus 1-3 (n = 7), rhinovirus (n = 5), respiratory syncytial virus (n = 4), and adenovirus (n = 4). All cases were immunocompromised patients who acquired new respiratory symptoms and/or radiologic abnormalities suggesting a pulmonary infection. Twenty-five patients (74%) did not respond to initial broad-spectrum antibiotics, and 11 patients (33%) required intensive care for respiratory failure. The overall mortality rate at 1 month was 24%. In patients with a sole viral pathogen identified in their BAL, the mortality rate was 39%. In lung transplant recipients (n = 10), the mean FEV1 decreased from 2.2 to 1.9 L/s before and during the infection episode, respectively (p < 0.01); 3 months later, 60% of the patients had still not completely recovered to baseline values. Conclusion: Respiratory viruses recovered in BAL samples of immunocompromised patients are associated with severe lower respiratory complications. In lung transplant recipients, we observed a persisting impairment of pulmonary function.
引用
收藏
页码:1033 / 1039
页数:7
相关论文
共 39 条
  • [1] PARAINFLUENZA AND INFLUENZA-VIRUS INFECTIONS IN PEDIATRIC ORGAN TRANSPLANT RECIPIENTS
    APALSCH, AM
    GREEN, M
    LEDESMAMEDINA, J
    NOUR, B
    WALD, ER
    [J]. CLINICAL INFECTIOUS DISEASES, 1995, 20 (02) : 394 - 399
  • [2] RESPIRATORY VIRUS-INFECTIONS DURING ANTICANCER TREATMENT IN CHILDREN
    AROLA, M
    RUUSKANEN, O
    ZIEGLER, T
    SALMI, TT
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (08) : 690 - 694
  • [3] Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy
    Aslan, T
    Fassas, AT
    Desikan, R
    Siegel, D
    Munshi, NC
    Mehta, J
    Singhal, S
    Barlogie, B
    Anaissie, E
    [J]. BONE MARROW TRANSPLANTATION, 1999, 24 (05) : 505 - 509
  • [4] Baron S, 1992, INTERFERON PRINCIPLE, P1
  • [5] Bowden Raleigh A., 1997, American Journal of Medicine, V102, P27, DOI 10.1016/S0002-9343(97)00007-7
  • [6] Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial
    Carman, WF
    Elder, AG
    Wallace, LA
    McAulay, K
    Walker, A
    Murray, GD
    Stott, DJ
    [J]. LANCET, 2000, 355 (9198) : 93 - 97
  • [7] Centers for Disease Control and Prevention, 1997, MMWR RECOMM REP, V47, P1
  • [8] RECOVERY OF VIRUSES OTHER THAN CYTOMEGALOVIRUS FROM BRONCHOALVEOLAR LAVAGE FLUID
    CONNOLLY, MG
    BAUGHMAN, RP
    DOHN, MN
    LINNEMANN, CC
    [J]. CHEST, 1994, 105 (06) : 1775 - 1781
  • [9] Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X
  • [10] Treatment of RSV pneumonia in adults - Evidence of ribavirin effectiveness?
    Dominguez, KD
    Mercier, RC
    [J]. ANNALS OF PHARMACOTHERAPY, 1999, 33 (06) : 739 - 741